Condition: Dystrophic Epidermolysis Bullosa · Recessive Dystrophic Epidermolysis Bullosa · Dominant Dystrophic Epidermolysis Bullosa · Sponsor: Krystal Biotech, Inc.
The main objective of this prospective, observational, long-term follow-up (LTFU) study is to evaluate the long-term safety profile of the gene therapy products evaluated by Krystal Biotech, Inc. which have a shared backbone of HSV-1, in participants who received at least one dose of investigational product (IP).
This description comes directly from the study's public registry record.
Brittani Agostini · 4125865830 · bagostini@krystalbio.com
Always discuss trial participation with your own doctor first.
| Mission Dermatology Center | Rancho Santa Margarita, California, United States | Recruiting |
| Stanford University | Redwood City, California, United States | Recruiting |
| Pediatric Skin Research | Coral Gables, Florida, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04917887